Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / MAGEA6



This biomarker is also known as:
  • CT1.6,
  • cancer/testis antigen 1.6,
  • Cancer/testis antigen 1.6,
  • cancer/testis antigen family 1, member 6,
  • MAGE-6 antigen,
  • MAGE-3b,
  • MAGE3B,
  • MAGE3B antigen,
  • melanoma antigen family A, 6,
  • MAGE6,
  • melanoma-associated antigen 6,

View in BioMuta


The members of the MAGEA protein family display 50-80% sequence identity among their members. MAGEA proteins are thought to play a role in tumor transformation or aspects of tumor progression. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. Alternative splicing results in multiple transcript variants.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

MAGEA6 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.